nach oben

Breast Cancer Research and Treatment

Erschienen in:

18.05.2020 | Preclinical study

High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer

verfasst von: Yang Li, Jun Qin, Junyi Wu, Xueming Dai, Junming Xu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oxidative stress-responsive kinase 1 (OSR1) plays a crucial role in regulating diverse cellular pathophysiologic functions, including ion homeostasis, development, differentiation, angiogenesis, invasive migration, and metastasis. Regardless, the clinical significance of OSR1 in breast cancer is scarce. The current study was conducted to evaluate the effect of OSR1 on the prognosis of patients with breast cancer with a long-term follow-up.

Methods

OSR1 expression in formalin-fixed and paraffin-embedded tissue specimens was analyzed. These specimens were collected from 551 evaluable breast cancer cases by immunohistochemistry (IHC). OSR1 expression was dichotomized based on the H-score in IHC. The effects of OSR1 levels on the clinicopathological attributes and survival prediction in patients with breast cancer were explored.

Results

Among 551 specimens, 183 (33.2%) exhibited high expression of OSR1 in tumor cells. High OSR1 levels were markedly correlated with histologic grade (P = 0.035), ER (P < 0.001) and PgR (P = 0.043) expression, lymph node involvement (P < 0.001), TNM stage (P < 0.001), and axillary surgery procedures (P = 0.003). Univariate analysis results indicate that patients with high OSR1 expression had significantly poor overall survival (P < 0.001), distant disease-free survival (P < 0.001), and breast cancer-specific survival (P < 0.001). Multivariable Cox regression analyses suggest that OSR1 expression was an independent predictive marker of poor prognosis and lymph node metastasis (HR 3.224, 95% CI 1.182–8.702, P = 0.023) in patients with breast cancer.

Conclusions

Our findings indicate that OSR1 is a significantly independent prognosis index for patients with breast cancer with respect to distant disease-free survival, overall survival, and breast cancer-specific survival. High OSR1 expression caused an increase in deaths specifically attributed to breast cancer and was related to increased lymph node metastasis. However, the precise cellular mechanisms for OSR1 in breast cancer require further research.

Gorbounov M, Carleton NM, Asch-Kendrick RJ, Xian L, Rooper L, Chia L, Cimino-Mathews A, Cope L, Meeker A, Stearns V, Veltri RW, Bae YK, Resar LMS (2019) High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05419-1 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551 CrossRefPubMed

Wu Q, Li J, Sun S, Zhu S, Chen C, Wu J, Liu Q, Wei W, Sun S (2017) Breast carcinoma in situ: an observational study of tumor subtype treatment and outcomes. Oncotarget 8:2361–2371. https://doi.org/10.18632/oncotarget.13785 CrossRefPubMed

Tamari M, Daigo Y, Nakamura Y (1999) Isolation and characterization of a novel serine threonine kinase gene on chromosome 3p22-21.3. J Hum Genet 44:116–120. https://doi.org/10.1007/s100380050121 CrossRefPubMed

Pedro NF, Biselli JM, Maniglia JV, de Santi-Neto D, Pavarino ÉC, Goloni-Bertollo EM, Biselli-Chicote PM (2018) Candidate biomarkers for oral squamous cell carcinoma: differential expression of oxidative stress-related genes. APJCP 19:1343. https://doi.org/10.22034/APJCP.2018.19.5.1343 CrossRefPubMedPubMedCentral

Piechotta K, Lu J, Delpire E (2002) Cation chloride cotransporters interact with the stress-related kinases Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1). J Biol Chem 277:50812–50819. https://doi.org/10.1074/jbc.m208108200 CrossRefPubMed

Mazorra Z, Popa X, Garcia B, Huerta V, Viada C, Neninger E, Rodriguez P, Gonzalez Z, Gonzalez A, Crombet T (2018) PO-486 Surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimised EGF-based vaccination schedule. BMJ Publishing Group Limited, LondonCrossRef

Tahmasbpour E, Ghanei M, Qazvini A, Vahedi E, Panahi Y (2016) Gene expression profile of oxidative stress and antioxidant defense in lung tissue of patients exposed to sulfur mustard. Mutat Res Genet Toxicol Environ Mutagen 800:12–21. https://doi.org/10.1016/j.mrgentox.2016.03.006 CrossRefPubMed

Gallolu Kankanamalage S, Lee A-Y, Wichaidit C, Lorente-Rodriguez A, Shah AM, Stippec S, Whitehurst AW, Cobb MH (2017) WNK1 is an unexpected autophagy inhibitor. Autophagy 13:969–970. https://doi.org/10.1080/15548627.2017.1286431 CrossRefPubMedPubMedCentral

10.

Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD (2008) Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 14:4821–4829. https://doi.org/10.1158/1078-0432.ccr-07-4568 CrossRefPubMedPubMedCentral

11.

Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP (2012) DNA methylation biomarkers for lung cancer. Tumor Biol 33:287–296. https://doi.org/10.1016/b978-0-12-801899-6.00013-9 CrossRef

12.

Selvan L, Danda R, Madugundu A, Puttamallesh V, Sathe G, Krishnan U, Khetan V, Rishi P, Prasad T, Pandey A (2018) Phosphoproteomics of retinoblastoma: a pilot study identifies aberrant kinases. Molecules 23:1454. https://doi.org/10.3390/molecules23061454 CrossRefPubMedCentral

13.

Treiber JM, Steed TC, Brandel MG, Patel KS, Dale AM, Carter BS, Chen CC (2018) Molecular physiology of contrast enhancement in glioblastomas: an analysis of the cancer imaging archive (TCIA). J Clin Neurosci 55:86–92. https://doi.org/10.1016/j.jocn.2018.06.018 CrossRefPubMed

14.

Both J, Krijgsman O, Bras J, Schaap GR, Baas F, Ylstra B, Hulsebos TJ (2014) Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS ONE 9:e115835. https://doi.org/10.1371/journal.pone.0115835 CrossRefPubMedPubMedCentral

15.

Anselmo AN, Earnest S, Chen W, Juang Y-C, Kim SC, Zhao Y, Cobb MH (2006) WNK1 and OSR1 regulate the Na⁺, K⁺, 2Cl⁻ cotransporter in HeLa cells. Proc Natl Acad Sci 103:10883–10888. https://doi.org/10.1073/pnas.0604607103 CrossRefPubMedPubMedCentral

16.

Zhu W, Begum G, Pointer K, Clark PA, Yang S-S, Lin S-H, Kahle KT, Kuo JS, Sun D (2014) WNK1-OSR1 kinase-mediated phospho-activation of Na⁺-K⁺-2Cl⁻ cotransporter facilitates glioma migration. Mol Cancer 13:31. https://doi.org/10.1186/1476-4598-13-31 CrossRefPubMedPubMedCentral

17.

Du E, Lu C, Sheng F, Li C, Li H, Ding N, Chen Y, Zhang T, Yang K, Xu Y (2018) Analysis of potential genes associated with primary cilia in bladder cancer. Cancer Manag Res 10:3047. https://doi.org/10.2147/cmar.s175419 CrossRefPubMedPubMedCentral

18.

Hortobagyi GN, Connolly JL, D'Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Giuliano AE (2017) American Joint Committee on Cancer (AJCC). AJCC cncer staging manual, 8th edn. Springer, Chicago

19.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290–303. https://doi.org/10.3322/caac.21393 CrossRefPubMed

20.

Grunkin M, Raundahl J, Foged NT (2011) Practical considerations of image analysis and quantification of signal transduction IHC staining. Signal Transduction Immunohistochemistry. Springer, New York, pp 143–154CrossRef

21.

Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12:R92. https://doi.org/10.1186/bcr2771 CrossRefPubMedPubMedCentral

22.

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindström L, Bergh J (2011) HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125:553–561. https://doi.org/10.1007/s10549-010-1029-2 CrossRefPubMed

23.

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608. https://doi.org/10.1200/jco.2011.37.2482 CrossRefPubMed

24.

Engstrøm MJ, Valla M, Bofin AM (2017) Basal markers and prognosis in luminal breast cancer. Breast Cancer Res Treat 163:207–217. https://doi.org/10.1007/s10549-017-4182-z CrossRefPubMed

25.

Delpire E, Gagnon KB (2006) SPAK and OSR1, key kinases involved in the regulation of chloride transport. Acta Physiol 187:103–113. https://doi.org/10.1111/j.1748-1716.2006.01565.x CrossRef

26.

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247:207–213. https://doi.org/10.1097/sla.0b013e31812e6a73 CrossRefPubMed

27.

Conti A, Luchini A, Benassi MS, Magagnoli G, Pierini M, Piccinni-Leopardi M, Quattrini I, Pollino S, Picci P, Liotta LA (2018) Circulating candidate biomarkers in giant cell tumors of bone. Proteom Clin Appl 12:1800041. https://doi.org/10.1002/prca.201800041 CrossRef

28.

Goldhirsch A, Winer EP, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H-J, Members P, Albain KS, André F (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223. https://doi.org/10.1159/000351222 CrossRefPubMedPubMedCentral

29.

Group EBCTC (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716. https://doi.org/10.1016/j.breastdis.2012.06.011 CrossRef

30.

Villa F, Goebel J, Rafiqi FH, Deak M, Thastrup J, Alessi DR, van Aalten DM (2007) Structural insights into the recognition of substrates and activators by the OSR1 kinase. EMBO Rep 8:839–845. https://doi.org/10.2210/pdb2v3s/pdb CrossRefPubMedPubMedCentral

31.

Stossel TP (1993) On the crawling of animal cells. Science 260:1086–1094. https://doi.org/10.1126/science.8493552 CrossRefPubMed

32.

Gagnon KB, Rios K, Delpire E (2011) Functional insights into the activation mechanism of Ste20-related kinases. Cell Physiol Biochem 28:1219–1230. https://doi.org/10.1159/000335854 CrossRefPubMed

33.

Chen W, Yazicioglu M, Cobb MH (2004) Characterization of OSR1, a member of the mammalian Ste20p/germinal center kinase subfamily. J Biol Chem 279:11129–11136. https://doi.org/10.1074/jbc.m313562200 CrossRefPubMed

34.

Papakonstanti EA, Stournaras C (2002) Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell 13:2946–2962. https://doi.org/10.1091/mbc.02-01-0599 CrossRefPubMedPubMedCentral

35.

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501. https://doi.org/10.1016/s0092-8674(01)00237-9 CrossRefPubMed

36.

Cusick JK, Xu L-G, Bin L-H, Han K-J, Shu H-B (2006) Identification of RELT homologues that associate with RELT and are phosphorylated by OSR1. Biochem Biophys Res Commun 340:535–543. https://doi.org/10.1016/j.bbrc.2005.12.033 CrossRefPubMed

37.

Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW (2005) High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307:1621–1625. https://doi.org/10.1126/science.1105776 CrossRefPubMed

38.

Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, De Medina SGD, Segraves R, De Rycke Y, Elvin P, Cassidy A, Spraggon C (2006) Regional copy number–independent deregulation of transcription in cancer. Nat Genet 38:1386. https://doi.org/10.1038/ng1923 CrossRefPubMed

Titel: High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer
verfasst von: Yang Li
Jun Qin
Junyi Wu
Xueming Dai
Junming Xu
Publikationsdatum: 18.05.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05671-w

Springer Medizin

High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity

HER2-targeted therapy influences CTC status in metastatic breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer

Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie